

SUPPLEMENTARY FIGURE LEGEND

Supplemental Figure 1. Kaplan-Meier OS curve of patients enrolled onto Trial A with (A) a family history of pancreatic ductal adenocarcinoma (PDAC) or (B) breast or ovarian cancer

SUPPLEMENTARY TABLE

Supplemental Table 1. Treatment schema for Trials A and B

	Trial A (9625)	Trial B (9940)
Radiation Therapy	Split-course (2 weeks off) 2.5 Gy/24h x 20 treatments	Continuous (split-course optional) 1.8 Gy/24h x 25-30 treatments
5-fluorouracil	Bolus (400 mg/m ² /24h IV x 3 days)	Continuous infusion (175 mg/m ² /24h IV x 28 days)
Leucovorin	20 mg/m ² /24h IV bolus on Days 1-3, 29-31, 71-73 99-101, 127-129, 155-157	20 mg/m ² /24h IV bolus on Days 1, 8, 15, 22, 127, 134, 141, 148, 176, 183, 190, 197
Mitomycin C	10 mg/m ² /day on Days 1, 71, 127	8 mg/m ² /day on Days 1, 49, 126
Dipyridamole	Days 0-3, 28-31, 70-73, 98-101, 126-129, 154-157 (75 mg/day p.o. QID)	75 mg/day p.o. TID x 28 days
Treatment Sequence	<p>Split-course chemoradiation (2 cycles of concurrent chemo)</p> <p style="text-align: center;">↓</p> <p style="text-align: center;">Chemo x 4 cycles</p>	<p>Chemo x 1 cycle</p> <p style="text-align: center;">↓</p> <p>Continuous chemoradiation (1 cycle of concurrent chemo)</p> <p style="text-align: center;">↓</p> <p style="text-align: center;">Chemo x 2 cycles*</p>

*The final cycle of chemotherapy administered in Trial B did not include mitomycin C